We are on a mission to bring treatments to patients faster

ABOUT US

The team behind the mission

Paul walked into the doctor with a stomach ache and left with a terminal diagnosis: stage 3 pancreatic cancer. When Kim (Paul's best friend and our CEO) found out, she did everything she could to get him into a clinical trial that could save his life. Unfortunately, Paul died waiting while the most promising treatments were getting "trial ready".

This lit a fire in her to figure out a way to accelerate clinical trials. Since then, she built a team of experts in AI, business, technology, and life sciences to help accomplish our mission: to bring treatments to patients faster, because they don't have time to wait. Our team is bonded by this mission and each of us has a personal story that collectively pushes us to breakdown traditional barriers and re-imagine clinical trials.

Along the way we've been fortunate to participate in incubators and accelerators that have been integral to getting us where we are today. Evonexus, Nex Cubed, Dreamit, Nvidia Inception, and JLabs have all played a critical role in our evolution.

this is our OG TEAM.                                                            *the acquisition of trials.ai by zs has enabled our team to add incredible new members                                                            **stay tuned as we update this section with new faces in the coming weeks! 

Kim-web

Kim Walpole

CEO
David-web

David Fogel

CHIEF SCIENTIST
Tom-web

Tom Walpole

CO-FOUNDER AND CTO
Josh-web

Josh Stanley

PRODUCT
Leo-web

Leo Spiegel

ADVISOR
Giles-web

Tom Giles

ADVISOR

Awards

Digital Trail Blazer Finalist

Kim Walpole and David Fogel named to Ai Thought Leaders List

David Fogel Ph.D named to the top 100 Ai Leaders in Drug Discovery & Healthcare

San Diego Venture Group

Cool Company 2018

Digital Pharma West

Barracuda Bowl Winner 2018

CONTACT

Let’s make trials better and faster, together.

How AI can improve trials’ likelihood of success

Read latest paper published by our Chief Scientist, David Fogel Ph.D, in Contemporary Clinical Trials Communications.